CoChat

Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential

Open access

The DOI matches its Crossref record; 174 of the 181 references it cites were found in a registry or an index.

Abstract

Age-related macular degeneration (AMD) is a complex and multifactorial disease, resulting from the interaction of environmental and genetic factors. The continuous discovery of associations between genetic polymorphisms and AMD gives reason for the pivotal role attributed to the genetic component to its development. In that light, genetic tests and polygenic scores have been created to predict the risk of development and response to therapy. Still, none of them have yet been validated. Furthermore, there is no evidence from a clinical trial that the determination of the individual genetic structure can improve treatment outcomes. In this comprehensive review, we summarize the polymorphisms of the main pathogenetic ways involved in AMD development to identify which of them constitutes a potential therapeutic target. As complement overactivation plays a major role, the modulation of targeted complement proteins seems to be a promising therapeutic approach. Herein, we summarize the complement-modulating molecules now undergoing clinical trials, enlightening those in an advanced phase of trial. Gene therapy is a potential innovative one-time treatment, and its relevance is quickly evolving in the field of retinal diseases. We describe the state of the art of gene therapies now undergoing clinical trials both in the field of complement-suppressors and that of anti-VEGF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232113280

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of pathways involved in AMD pathogenesis and connections between them. Complement activation is the crucial mechanism. The last part of the cascade is the MAC activation, which releases various mediators of tissue damage: inflammatory molecules, tissue remodelling molecules, and VEGF. Oxidative stress is also considered a major risk factor in AMD as the retina is a high-rate-metabolism tissue. Through the Fenton reaction and peroxidation, tissue injury occurs, and the complement is triggered, thus perpetuating inflammation. ROS cause the production of misfolded proteins and DNA modification, particularly of mitochondrial DNA. If DNA-repairing mechanisms are less efficient because of age-related or genetic deficiencies, DNA changes and instability occur. RPE is the regulator of cholesterol input and output. When it becomes less performant, lipids and oxidized lipids aggregate, similarly to what happens in the atherosclerotic process. MAC: membrane attack complex; IL-1: interleukin 1; TNF: tumoral necrosis factor; IL-8: interleukin 8; IL-6: interleukin 6; MMP-2 matrix metalloproteinase 2; MMP-9 matrix metalloproteinase 9; ROS: reactive species of oxygen, RPE: retinal pigment epithelium.
Figure 1 Summary of pathways involved in AMD pathogenesis and connections between them. Complement activation is the crucial mechanism. The last part of the cascade is the MAC activation, which releases various mediators of tissue damage: inflammatory molecules, tissue remodelling molecules, and VEGF. Oxidative stress is also considered a major risk factor in AMD as the retina is a high-rate-metabolism tissue. Through the Fenton reaction and peroxidation, tissue injury occurs, and the complement is triggered, thus perpetuating inflammation. ROS cause the production of misfolded proteins and DNA modification, particularly of mitochondrial DNA. If DNA-repairing mechanisms are less efficient because of age-related or genetic deficiencies, DNA changes and instability occur. RPE is the regulator of cholesterol input and output. When it becomes less performant, lipids and oxidized lipids aggregate, similarly to what happens in the atherosclerotic process. MAC: membrane attack complex; IL-1: interleukin 1; TNF: tumoral necrosis factor; IL-8: interleukin 8; IL-6: interleukin 6; MMP-2 matrix metalloproteinase 2; MMP-9 matrix metalloproteinase 9; ROS: reactive species of oxygen, RPE: retinal pigment epithelium.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Busbee, 2021, Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial), Investig. Ophthalmol. Vis. Sci., 62, 352

Cited by

See all 29

Metadata

Authors
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R.
Affiliations
  • Humanitas University (IT)
  • Humanitas Castelli (IT)
Corresponding author
Stradiotto, Elisa
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-10-31
Volume
23
Issue
21
Pages
13280
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4308124848
Cited by
29
References
181
Citations by year
2026: 4 · 2025: 6 · 2024: 14 · 2023: 5
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
age-related macular degeneration, genetic polymorphism, genetic risk prediction, polygenic risk score, complement overactivation, gene therapy, anti-VEGF therapy, retinal disease, therapeutic target
MeSH terms
Complement System Proteins, Humans, Macular Degeneration, Polymorphism, Genetic, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.